"Adenine" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A purine base and a fundamental unit of ADENINE NUCLEOTIDES.
Descriptor ID |
D000225
|
MeSH Number(s) |
D03.633.100.759.138
|
Concept/Terms |
Adenine- Adenine
- Vitamin B 4
- 4, Vitamin B
- B 4, Vitamin
|
Below are MeSH descriptors whose meaning is more general than "Adenine".
Below are MeSH descriptors whose meaning is more specific than "Adenine".
This graph shows the total number of publications written about "Adenine" by people in this website by year, and whether "Adenine" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
Year | Major Topic | Minor Topic | Total |
---|
1995 | 0 | 3 | 3 |
1996 | 1 | 1 | 2 |
1998 | 1 | 0 | 1 |
1999 | 0 | 1 | 1 |
2000 | 0 | 1 | 1 |
2001 | 0 | 1 | 1 |
2002 | 0 | 1 | 1 |
2003 | 1 | 0 | 1 |
2004 | 0 | 1 | 1 |
2005 | 2 | 1 | 3 |
2006 | 1 | 2 | 3 |
2007 | 2 | 3 | 5 |
2008 | 0 | 2 | 2 |
2009 | 0 | 2 | 2 |
2010 | 0 | 1 | 1 |
2011 | 0 | 1 | 1 |
2012 | 0 | 5 | 5 |
2013 | 0 | 8 | 8 |
2014 | 1 | 9 | 10 |
2015 | 0 | 24 | 24 |
2016 | 0 | 17 | 17 |
2017 | 1 | 18 | 19 |
2018 | 2 | 34 | 36 |
2019 | 2 | 28 | 30 |
2020 | 12 | 9 | 21 |
2021 | 14 | 7 | 21 |
2022 | 0 | 10 | 10 |
2023 | 1 | 4 | 5 |
2024 | 5 | 0 | 5 |
To return to the timeline,
click here.
Below are the most recent publications written about "Adenine" by people in Profiles.
-
Limited efficacy for ibrutinib and venetoclax in T-prolymphocytic leukemia: results from a phase 2 international study. Blood Adv. 2024 Feb 27; 8(4):842-845.
-
Phase I Study of mTORC1/2 Inhibitor Sapanisertib (CB-228/TAK-228) in Combination with Metformin in Patients with mTOR/AKT/PI3K Pathway Alterations and Advanced Solid Malignancies. Cancer Res Commun. 2024 02 12; 4(2):378-387.
-
Phase I study of sapanisertib (CB-228/TAK-228/MLN0128) in combination with ziv-aflibercept in patients with advanced solid tumors. Cancer Med. 2024 Feb; 13(3):e6877.
-
Absence of BTK, BCL2, and PLCG2 Mutations in Chronic Lymphocytic Leukemia Relapsing after First-Line Treatment with Fixed-Duration Ibrutinib plus Venetoclax. Clin Cancer Res. 2024 02 01; 30(3):498-505.
-
Cost Effectiveness of Zanubrutinib Versus Ibrutinib in Relapsed or Refractory Chronic Lymphocytic Leukemia. Pharmacoeconomics. 2024 Apr; 42(4):409-418.
-
Safety and efficacy of ibrutinib in combination with rituximab and lenalidomide in previously untreated follicular and marginal zone lymphoma: An open label, phase 2 study. Cancer. 2024 03 15; 130(6):876-885.
-
Venetoclax consolidation in high-risk CLL treated with ibrutinib for =1 year achieves a high rate of undetectable MRD. Leukemia. 2023 07; 37(7):1444-1453.
-
Changes in local tissue microenvironment in response to subcutaneous long-acting delivery of tenofovir alafenamide in rats and non-human primates. J Control Release. 2023 06; 358:116-127.
-
Comparative Study of Adenosine Analogs as Inhibitors of Protein Arginine Methyltransferases and a Clostridioides difficile-Specific DNA Adenine Methyltransferase. ACS Chem Biol. 2023 04 21; 18(4):734-745.
-
Bruton tyrosine kinase inhibitors in the management of Waldenstr?m macroglobulinemia. Am J Hematol. 2023 02; 98(2):338-347.